Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.01 USD
-0.20 (-2.44%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.02 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TBPH 8.01 -0.20(-2.44%)
Will TBPH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Best Momentum Stocks to Buy for July 15th
Other News for TBPH
Unveiling 4 Analyst Insights On Theravance Biopharma
Buy Rating Affirmed for Theravance Biopharma on Yupelri Growth and Ampreloxetine Pipeline Progress
Seth Klarman's Complete Exit from Theravance Biopharma Inc
Theravance Biopharma to Participate in an Upcoming Investor Conference
Tracking Seth Klarman's Baupost Group Holdings - Q2 2024 Update